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Abstract
In vivo microdialysis in C57BL/6J (B6) mouse was used to
test the hypothesis that activating adenosine A2A receptors
in the pontine reticular formation (PRF) increases acetyl-
choline (ACh) release and rapid eye movement (REM)
sleep. Eight concentrations of the adenosine A2A receptor
agonist 2-p-(2-carboxyethyl)phenethylamino-5¢-N-ethylcarb-
oxamidoadenosine hydrochloride (CGS 21680; CGS) were
delivered to the PRF and ACh in the PRF was quantified.
ACh release was significantly increased by dialysis with
3 lM CGS and significantly decreased by dialysis with
10 and 100 lM CGS. Co-administration of the adenosine
A2A receptor antagonist 4-(2-[7-amino-2-(2-furyl)[1,2,4]tri-
azolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM 241385;
30 nM) blocked the CGS-induced increase in ACh release.
In a second series of experiments, CGS (3 lM) was deliv-
ered by dialysis to the PRF for 2 h while recording sleep
and wakefulness. CGS significantly decreased time in
wakefulness ()51% in h 1; )54% in h 2), increased time in
non-rapid eye movement (NREM) sleep (90% in h 1; 151%
in h 2), and increased both time in REM sleep (331% in
h 2) and the number of REM sleep episodes (488% in h 2).
The enhancement of REM sleep is consistent with the
interpretation that adenosine A2A receptors in the PRF of
the B6 mouse contribute to REM sleep regulation, in part,
by increasing ACh release in the PRF. A2A receptor acti-
vation may promote NREM sleep via GABAergic inhibition
of arousal promoting neurons in the PRF.
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Cholinergic neurotransmission at muscarinic receptors in the
pontine reticular formation (PRF) of cat (reviewed in
Baghdoyan and Lydic 2002; Lydic and Baghdoyan 2005)
and rat (Imeri et al. 1994; Bourgin et al. 1995; Kubin 2001)
plays an important role in generating the rapid eye movement
(REM) phase of sleep. Microinjection of the acetylcholin-
esterase inhibitor neostigmine into the PRF of C57BL/6J
(B6) mouse causes a REM sleep-like state (Lydic et al. 2002)
that is concentration-dependent (Douglas et al. 2005) and
blocked by the muscarinic receptor antagonists methoctr-
amine (Coleman et al. 2004a) and atropine (Douglas et al.
2005). These data demonstrate that in the B6 mouse a REM
sleep-like state is also produced by activation of muscarinic
receptors in the PRF. Cholinergic input to the PRF originates
from the laterodorsal tegmental and pedunculopontine teg-
mental (LDT/PPT) nuclei (reviewed in Steriade and
McCarley 2005). Acetylcholine (ACh) release in cat PRF
is significantly greater during REM sleep than during
wakefulness and non-rapid eye movement (NREM) sleep
(Kodama et al. 1990; Leonard and Lydic 1995, 1997).
Additional evidence supporting a role for pontine cholinergic
neurotransmission in REM sleep generation is provided by
studies demonstrating that electrical stimulation of the LDT/
PPT increases ACh release in the PRF (Lydic and Baghdoyan
1993) and increases REM sleep (Thakkar et al. 1996). In
addition, neurotoxic lesions of cholinergic LDT/PPT neurons
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cause a long-lasting inhibition of REM sleep (Webster and
Jones 1988).
Since the 1950s, the neuromodulator adenosine repeatedly
has been shown to promote NREM sleep (reviewed in
Benington and Heller 1995; Porkka-Heiskanen et al. 2002;
Basheer et al. 2004; Radulovacki 2005). Consistent with
these findings, adenosine antagonists such as caffeine and
theophylline enhance wakefulness and disrupt sleep (Fred-
holm et al. 1999; Shaw et al. 2000). There are four
adenosine receptor subtypes (A1, A2A, A2B and A3), all of
which couple to G proteins (Ribeiro et al. 2003). Inhibitory
G protein-coupled adenosine A1 receptors and stimulatory G
protein-coupled adenosine A2A receptors in the brain mediate
the sleep-inducing effects of adenosine (reviewed in Porkka-
Heiskanen et al. 2002; Basheer et al. 2004). Sleep is
increased by forebrain administration of adenosine, adeno-
sine receptor agonists or drugs that increase adenosine. These
forebrain sites include the substantia innominata (Porkka-
Heiskanen et al. 1997; Portas et al. 1997), basal forebrain
area (Basheer et al. 1999), rostral basal forebrain and
underlying subarachnoid space (Satoh et al. 1996, 1998,
1999; Hong et al. 2005), ventrolateral preoptic area
(Morairty et al. 2004), subarachnoid space anterior to the
ventrolateral preoptic area (Scammell et al. 2001), medial
preoptic area (Ticho and Radulovacki 1991; Mendelson
2000), and lateral pre-optic area (Methippara et al. 2005).
Fewer studies have investigated a sleep-related role for
adenosine in the brain stem (Rainnie et al. 1994; Portas et al.
1997; Porkka-Heiskanen et al. 2000; Arrigoni et al. 2001),
and very few studies have focused specifically on REM sleep
(Marks and Birabil 1998; Marks et al. 2003). Adenosine A1
and A2A receptor agonists have been shown to increase REM
sleep when microinjected into rat PRF (Marks and Birabil
1998; Marks et al. 2003). REM sleep enhancement by an
adenosine A2A receptor agonist, but not by an adenosine A1
receptor agonist, was blocked by the muscarinic receptor
antagonist atropine (Marks et al. 2003).
Enhancing cholinergic neurotransmission at muscarinic
receptors in the PRF is thought to be one common
mechanism by which a variety of neurotransmitters and
neuromodulators regulate REM sleep (reviewed in Baghdo-
yan and Lydic 2002; Lydic and Baghdoyan 2003, 2005).
Microdialysis studies in the striatum of freely moving rat
have shown that an adenosine A2A receptor agonist stimu-
lates ACh release (Kurokawa et al. 1996). In vitro studies in
striatum, hippocampus, motor nerve terminals and cortex
also have shown that adenosine A2A receptor agonists
increase ACh release (reviewed in Sebastiao and Ribeiro
1996). It is not known whether activation of adenosine A2A
receptors in mouse PRF increases ACh release and increases
REM sleep. The present study used in vivo microdialysis and
electrographic recordings of sleep and wakefulness to test the
hypothesis that dialysis administration of the adenosine A2A
receptor agonist 2-p-(2-carboxyethyl)phenethylamino-5¢-N-
ethylcarboxamidoadenosine hydrochloride (CGS 21680;
CGS) into the PRF of B6 mouse increases both ACh release
and REM sleep. Portions of these data have been presented in
abstract form (Coleman et al. 2004b).
Experimental procedures
Animals and surgery
All experiments used adult male B6 mice (n ¼ 42; mean
weight ¼ 26 g; Jackson Laboratory, Bar Harbor, ME, USA) and
were approved by the University of Michigan Committee on Use
and Care of Animals. The studies were performed in accordance
with the US Public Health Service Policy on Humane Care and
Use of Laboratory Animals (National Institutes of Health
Publication 80–23). Mice were housed individually in a tempera-
ture-controlled room under constant illumination with free access
to food and water.
Mice were anesthetized with isoflurane (induction: 2.5%;
maintenance: 1.2%; delivered in 100% oxygen) (Abbott Laborator-
ies, North Chicago, IL, USA) and placed in a David Kopf (Tujunga,
CA, USA) Model 962 stereotaxic frame with a Model 923 mouse
head holder adaptor and anesthesia mask. Two groups of mice were
surgically implanted for subsequent neurochemical studies, as
previously described in detail (Coleman et al. 2004a,c). Mice in
the first group were used to measure PRF ACh release during drug
delivery to the PRF. The PRF includes the pontine reticular nucleus,
oral part (PnO) and the pontine reticular nucleus, caudal part (PnC)
(Paxinos and Franklin 2001). To access the PRF, a craniotomy was
made 4.72 mm posterior to bregma and 0.75 mm lateral to the
sagittal suture according to the mouse brain atlas (Paxinos and
Franklin 2001). A CMA/7 guide cannula (CMA Microdialysis,
North Chelmsford, MA, USA) was lowered 4.2 mm below the skull
surface and secured in place with dental acrylic. A second group of
mice was used to record states of sleep and wakefulness during
dialysis drug delivery to the PRF. In addition to a guide cannula
aimed for the PRF, mice in the second group were implanted with
electrodes for recording the electroencephalogram (EEG) and
electromyogram (EMG). The guide cannula, two stainless steel
anchor screws (Small Parts Inc., Miami Lakes, FL, USA), and a
plastic pedestal (Plastics One, Roanoke, VA, USA) containing the
electrodes were bonded to the skull with dental acrylic. Following a
1-week recovery period, mice were conditioned for 7 days by daily
handling and/or adapting them to a Plexiglas recording chamber
(BAS Raturn system; Bioanalytical Systems Inc., West Lafayette,
IN, USA).
Materials
Drugs delivered to the PRF by dialysis included the selective
adenosine A2A receptor agonist CGS (Sigma-Aldrich, St Louis,
MO, USA) and the selective adenosine A2A receptor antagonist
4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a] [1,3,5] triazin-5-yl-
amino]ethyl)phenol (ZM 241385; ZM; Tocris Cookson, Ballwin,
MO, USA). CGS was dissolved in Ringer’s solution (147 mM
NaCl; 2.4 mM CaCl2; 4.0 mM KCl). Neostigmine bromide
(0.1 lM; Sigma-Aldrich) was present in the Ringer’s solution
only for the experiments that measured ACh. Eight concentrations
of CGS (0.1, 0.3, 1, 3, 10, 30, 100 and 1000 lM) were used to
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perfuse the dialysis probe. ZM (30 nM) was co-delivered to the
probe with CGS (3 lM).
Microdialysis and ACh quantification
CMA/7 dialysis probes, used for all experiments, have a 1-mm long
by 0.24-mm diameter cuprophane membrane with a 6-kDa cut-off
(CMA Microdialysis). A dialysis probe was inserted into the guide
cannula and perfused continuously with Ringer’s solution at a flow
rate of 2 lL/min. The probe membrane extended 1 mm below the
end of the implanted guide cannula. Six dialysis samples (25 lL/
sample) were collected on ice while perfusing the probe with
Ringer’s solution (control). Using a CMA/110 liquid switch, the
perfusate was then changed to Ringer’s containing CGS or CGS
plus ZM and six additional dialysis samples were collected. Only
one concentration of CGS was administered per experiment, and
only one experiment was performed per mouse. All experiments
began between 10:00 and 11:00 h.
ACh in the dialysis samples was quantified using high perform-
ance liquid chromatography with electrochemical detection (HPLC/
EC; Bioanalytical Systems Inc.). A sample was injected into the
HPLC/EC system immediately after collection and carried in a
50-mM Na2HPO4 mobile phase (pH 8.5) through an analytical
column that separated ACh and choline. An immobilized enzyme
reactor column then proportionally converted the amount of ACh
and choline in the sample to hydrogen peroxide. The hydrogen
peroxide was detected by a platinum electrode (500 mV applied
potential) referenced to an Ag+/AgCl electrode. Chromgraph
software (Bioanalytical Systems Inc.) was used to digitize the
resulting signal and to generate chromatographic peaks. The amount
of ACh in a dialysis sample was determined by comparing the
chromatographic peak area produced by the dialysis sample to a
standard curve created immediately before each experiment.
The percent of ACh recovered by the dialysis probe was
determined in vitro before and after every experiment and compared
by t-test. If the pre- and post-experimental probe recovery values
were significantly different (p < 0.05), then the results from that
experiment were not included in the final data set. For all CMA/7
probes used to quantify ACh release, the average ± SD percent
recovery of ACh was 5.85 ± 0.35%.
Microdialysis drug delivery and recordings of sleep and
wakefulness
After being conditioned to the Plexiglas recording chamber, mice
exhibited normal amounts of wakefulness, NREM sleep and REM
sleep (Franken et al. 1999). The day before the experiment, a mouse
was placed in the recording chamber between 16:00 and 17:00 h
and left overnight. The next day the recording session began
between 10:00 and 11:00 h. One hour before the recording session,
the stylet of the microdialysis probe guide cannula was replaced
with a microdialysis probe. The probe was perfused with Ringer’s
solution until the start of the recording session. A CMA/110 liquid
switch then was turned to deliver Ringer’s solution (control) or
Ringer’s containing CGS for 2 h. During the 2-h dialysis period,
continuous recordings of EEG and EMG were obtained. The EEG
and EMG signals were amplified with a Grass Instruments (West
Warwick, RI, USA) model 15RXi amplifier. Signals were then
filtered (EEG, 0.3–30 Hz; EMG, 10–6K Hz), digitized at 128 Hz,
and recorded using Icelus software, as described previously
(Coleman et al. 2004a). Each mouse was used for only one dialysis
experiment.
Electrographic data and EEG power spectral analysis
The electrographic recordings were scored as wakefulness, NREM
sleep or REM sleep according to previously described criteria (Lydic
et al. 2002; Coleman et al. 2004a; Douglas et al. 2005). Dependent
measures of arousal state included mean 1-h values of per cent of
time spent in wakefulness, NREM sleep and REM sleep; the number
of REM sleep episodes; and the duration (min) of REM sleep
episodes. Latency to onset (min) of the first REM sleep episode also
was quantified.
EEG signals were evaluated using Fast Fourier transformation
(FFT) to reveal power spectra for consecutive 10-s epochs. Analyses
were conducted in 0.5 Hz increments for frequencies ranging from
0.5 to 25 Hz. The bins were averaged over five 1-min intervals of
EEG recording.
Histological evaluation of dialysis sites
Mice were deeply anesthetized and decapitated 3–5 days following
microdialysis. Brains were quickly removed and frozen. Serial
coronal brain stem sections were cut at a thickness of 40 lm, fixed
in hot (80C) paraformaldehyde vapor and stained with cresyl violet.
Dialysis probe sites were assigned posterior, lateral, and ventral
stereotaxic coordinates (mm) by comparing the stained tissue
sections to the mouse brain atlas (Paxinos and Franklin 2001).
Statistical analyses
Descriptive statistics (mean ± SEM) were used to summarize
dependent measures of ACh release and arousal state. ANOVA and
post-hoc comparisons with Bonferroni correction were used to
evaluate drug main effects on pontine ACh release using Statistical
Analysis System programs (release 9.1, SAS Institute, Cary, NC,
USA). Statistically significant differences in wakefulness, NREM
sleep and REM sleep between the experimental and control
conditions were evaluated by t-test. A probability value of
p < 0.05 indicated a statistically significant difference.
Results
CGS caused biphasic, concentration-dependent changes
in pontine reticular formation ACh release
The per cent change in ACh release during dialysis delivery
of CGS to the PRF is summarized in Fig. 1(a). One-way
ANOVA showed a significant CGS main-effect (F ¼ 8.24;
d.f. ¼ 7,16; p < 0.001). The numerator degrees of freedom
(d.f.) equals the number of CGS concentrations minus 1, and
the denominator d.f. equals the number of animals used
minus the number of CGS concentrations. Post-hoc multiple
comparisons test with Bonferroni correction showed that
3 lM CGS significantly (p < 0.001) increased ACh release
and 100 and 1000 lM CGS significantly (p < 0.005)
decreased ACh release compared with control levels.
Figure 1(b) demonstrates that all microdialysis probe sites
(n ¼ 24) were localized within the PRF. Mean ± SEM
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stereotaxic coordinates for the microdialysis sites were
4.95 ± 0.04 mm posterior to bregma, 0.73 ± 0.03 mm lateral
to the midline and 5.01 ± 0.06 mm ventral to the surface of
the skull.
The adenosine A2A antagonist ZM blocked the
CGS-induced increase in pontine reticular formation
ACh release
Figure 2(a) illustrates the time course of ACh release during
PRF dialysis with Ringer’s (control), CGS (3 lM), and CGS
(3 lM) plus ZM (30 nM). Control levels of ACh were stable
and not significantly different between experiments. Two-way
repeated measures ANOVA revealed a significant drug main-
effect (F ¼ 7.78; d.f. ¼ 2,8; p < 0.05), time main-effect
(F ¼ 2.75; d.f. ¼ 11,88; p < 0.005), and drug by time
interaction (F ¼ 1.88; d.f. ¼ 22,88; p < 0.05). The numera-
tor d.f. for the main effect of each factor (drug and time)
equals the number of factor levels minus 1. The numerator
d.f. for the drug by time interaction equals the d.f. for drug
multiplied by the d.f. for time. The denominator d.f. for the
drug main-effect equals the number of animals minus the
number of drug conditions. The denominator d.f. for the time
main-effect and drug by time interaction equals the total
number of dialysis samples minus the d.f. for the effects of
time and the drug by time interaction. Post-hoc multiple
comparisons statistic with Bonferroni correction showed that
3 lM CGS significantly (p < 0.005) increased ACh release
after 50 min of delivery (Fig. 2a, dialysis time 136.5 min).
Co-administration of CGS and ZM prevented the CGS-
induced increase in pontine ACh release.
All microdialysis sites (n ¼ 11) for the antagonist block-











































Fig. 1 CGS caused a biphasic, concentration-dependent change in
pontine reticular formation ACh release. (a) Eight concentrations of
CGS were administered to the PRF by dialysis. Three mice were used
per concentration of CGS, and each mouse contributed six samples
during dialysis with Ringer’s (Control) and six samples during dialysis
administration of CGS (filled bars). Asterisks indicate a significant
(p < 0.005) difference from mean control level (hatched bar) of ACh
release. (b) The histological section illustrates a representative dialysis
probe site localized to the PnO. The arrow marks the most ventral part
of the 1-mm long dialysis membrane. The sagittal diagram at right
(modified from Paxinos and Franklin 2001) schematizes a dialysis
probe in the PRF. The coronal diagrams at bottom are from the mouse
brain atlas (Paxinos and Franklin 2001) and illustrate microdialysis
sites in the PRF. Filled circles summarize dialysis sites from 24 mice
used to obtain the ACh release data in (a). The number at the top of
each coronal diagram indicates mm posterior to bregma.
(b)
(a)
Fig. 2 Co-administration of CGS and ZM to the pontine reticular for-
mation prevented the CGS-induced increase in ACh release. (a)
Sequential dialysis samples collected every 12.5 min from the PRF
show the time course of ACh release for Ringer’s (Control; n ¼ 3
mice), CGS (3 lM; n ¼ 3 mice), and co-administration of CGS (3 lM)
and ZM (30 nM; n ¼ 5 mice). These data summarize ACh measured in
132 dialysis samples obtained from 11 experiments. Control levels of
ACh release were established during the first 75 min of dialysis with
Ringer’s solution. The horizontal bar indicates that dialysis drug
delivery to the PRF occurred during min 75–150. CGS caused a sig-
nificant (p < 0.005) increase in ACh release over control levels
(asterisks). (b) Filled circles indicate the microdialysis sites for the 11
mice used in (a). The number at the top left of each diagram indicates
mm posterior to bregma (Paxinos and Franklin 2001).
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Fig. 2(b). Mean ± SEM stereotaxic coordinates for the
Fig. 2(b) microdialysis sites were 4.91 ± 0.06 mm posterior
to bregma, 0.7 ± 0.05 mm lateral to the midline, and
5.08 ± 0.07 mm ventral to the surface of the skull.
EEG power spectra during CGS delivery were similar to
baseline
Figure 3 summarizes the averaged EEG power spectra for
four mice during wakefulness, NREM sleep and REM sleep.
Insets show representative EEG and EMG recordings from
one mouse obtained during dialysis delivery of 3 lM CGS.
Figure 3(a) indicates that wakefulness was characterized by
a low amplitude, mixed frequency EEG (0.5–25 Hz) and a
high amplitude EMG. Figure 3(b) shows that NREM sleep
was characterized by increased delta power (0.5–4 Hz)
compared with wakefulness and REM sleep, high amplitude
EEG and an EMG of lower amplitude than the waking
EMG. Figure 3(c) illustrates that REM sleep was comprised
of increased theta power (5–9 Hz) with rhythmic low
amplitude EEG waves and a low amplitude EMG. Figure 3
shows that the EEG power spectra computed for wakeful-
ness, NREM sleep and REM sleep did not differ when
recordings without dialysis (baseline) were compared with
recordings during microdialysis (CGS). During pontine
reticular formation dialysis with CGS, sleep architecture
was normal and REM sleep always emerged from NREM
sleep.
Pontine reticular formation administration of CGS
decreased wakefulness and increased both NREM sleep
and REM sleep
Figure 4 summarizes group data showing the effects of
CGS on per cent time spent in wakefulness, NREM sleep
and REM sleep. In the first hour (Fig. 4a), CGS signifi-
cantly decreased wakefulness by 51% (t ¼ 3.07; d.f. ¼ 8;
p < 0.05) and increased NREM sleep by 90% (t ¼ 3.74;
d.f. ¼ 8; p < 0.01). There was no difference between time
spent in REM sleep during dialysis with CGS and Ringer’s
(control) in the first hour. In the second hour (Fig. 4b),
CGS significantly decreased wakefulness by 54% (t ¼
3.32; d.f. ¼ 8; p < 0.05), increased NREM sleep by 151%
(t ¼3.1; d.f. ¼ 8; p < 0.05), and increased REM sleep
by 331% (t ¼ 2.94; d.f. ¼ 8; p < 0.05) compared with
control.
The number of REM sleep episodes in the first hour of
CGS administration was not significantly different from
control (Fig. 5a). In the second hour, CGS caused a
significant increase (t ¼ 2.83; d.f. ¼ 8; p < 0.05) in the
number of REM sleep episodes (Fig. 5b). Pontine CGS had
no effect on REM sleep latency and no effect on duration of
individual REM sleep episodes in the first or the second hour
(data not shown).
Figure 5(c) shows that all microdialysis sites for the CGS
sleep studies were localized to the PRF. Mean ± SEM
stereotaxic coordinates for the microdialysis sites were
4.92 ± 0.05 mm posterior to bregma, 0.79 ± 0.06 mm lateral
to the midline, and 5.2 ± 0.09 mm ventral to the surface of
the skull. The microdialysis sites for the sleep studies
(Figs 3–5) did not differ from the microdialysis sites for the
ACh quantification studies (Figs 1 and 2).
Discussion
Dialysis administration of the adenosine A2A receptor agonist
CGS into the PRF of awake B6 mouse caused a concentra-
tion-dependent change in ACh release. The increase in ACh




































5 10 15 20
Frequency (Hz)




























































Fig. 3 EEG power spectra for sleep and wakefulness during baseline
(no microdialysis) recordings and during drug delivery to the PRF by
dialysis (CGS). The data summarize averaged EEG power in 0.5 Hz
frequency intervals (n ¼ 4 mice). Insets: 10-s intervals of EEG and
EMG recordings during CGS administration show electrographic fea-
tures that are similar to those of baseline recordings during wakeful-
ness (a), NREM sleep (b), and REM sleep (c). There were no
significant differences in EEG power comparing baseline and CGS.
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tering the adenosine A2A receptor antagonist ZM. These
findings support the interpretation that adenosine A2A
receptors in the PRF stimulate ACh release. Additional data
demonstrated that the same concentration of CGS that
increased ACh release when administered into the PRF also
increased REM sleep. This finding is consistent with
previous data showing that microinjection of CGS into rat
PRF caused REM sleep enhancement (Marks et al. 2003).
The present results show for the first time that administering
CGS to the PRF caused a significant increase in NREM
sleep. The mechanisms by which adenosine receptors in the
PRF contribute to the regulation of sleep are considered
below.
Modulation of ACh release in the PRF by adenosine A2A
and A1 receptors
Dialysis administration of CGS (3 lM) into the PRF




































































Fig. 5 CGS increased the number of REM sleep episodes. (a) In the
first hour of pontine reticular formation dialysis with CGS (3 lM; n ¼ 5
mice), the number of REM sleep episodes was not different from
Ringer’s (Control; n ¼ 5 mice). (b) The number of REM sleep epi-
sodes was significantly (p < 0.05) increased over control values in the
second hour of dialysis with CGS. Asterisk indicates a significant
(p < 0.05) difference from mean control level. (c) Filled circles localize
microdialysis sites for the 10 mice used for the CGS sleep studies
(Figs 4 and 5). The number at the top left of each diagram indicates
mm posterior to bregma (Paxinos and Franklin 2001). All drug delivery




























































Fig. 4 CGS altered the per cent of time spent in wakefulness, NREM
sleep and REM sleep. Per cent state values represent data from five
mice during dialysis with Ringer’s (Control) and five mice during
dialysis with CGS (3 lM). Asterisks indicate a significant (p < 0.05)
difference from control. (a) In the first hour of CGS delivery, NREM
sleep was significantly increased and wakefulness was significantly
decreased. (b) During the second hour, CGS delivery caused a sig-
nificant increase in REM sleep. NREM sleep also was increased and
wakefulness was decreased.
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finding is similar to the effect of 3 lM CGS on ACh release
in rat striatum (Kurokawa et al. 1996). Co-administration of
CGS and the adenosine A2A receptor antagonist ZM into the
PRF blocked the increase in ACh release caused by CGS
(Fig. 2). This finding supports the conclusion that the CGS-
evoked increase in ACh release is mediated by adenosine
A2A receptors in the PRF.
The present study also found that dialysis with higher
concentrations of CGS (100 and 1000 lM) significantly
decreased ACh release in the PRF (Fig. 1). CGS has an
approximately 200-fold higher affinity for adenosine A2A
receptors than for adenosine A1 receptors (Jarvis et al. 1989).
Thus, at high concentrations, CGS binds to adenosine A1
receptors (Klotz 2000). Functional evidence indicates that
both adenosine A1 and A2A receptors can coexist on the same
nerve terminal to, respectively, inhibit or enhance neuro-
transmitter release (Sebastiao and Ribeiro 2000; Wardas
2002). Therefore, the decrease in ACh release caused by
higher concentrations of CGS (Fig. 1) may have resulted
from activation of adenosine A1 receptors in the PRF. This
interpretation is reinforced by studies showing that dialysis
administration of the adenosine A1 agonist N
6-p-sulfo-
phenyladenosine to cat PRF decreased ACh release in the
PRF (Tanase et al. 2003). This interpretation also fits with
recent data showing that, in the lateral preoptic area,
adenosine has opposite effects on sleep and wakefulness,
depending upon the adenosine receptor subtype activated.
Activation of lateral preoptic area adenosine A1 receptors
increases wakefulness, whereas activation of adenosine A2A
receptors increases sleep (Methippara et al. 2005).
Pontine reticular formation CGS inhibits wakefulness
and promotes sleep
PRF administration of CGS (3 lM) decreased the time spent
awake and increased the time spent asleep (Fig. 4). The EEG
power spectra (Fig. 3) and the EEG and EMG recordings
(Fig. 3 insets) for each arousal state during CGS adminis-
tration were similar to those obtained during dialysis with
Ringer’s (control) and to those reported previously for B6
mouse (Franken et al. 1998; Lydic et al. 2002). Thus, the
enhanced sleep produced by CGS is electrographically
homologous to natural sleep.
Dialysis administration of 3 lM CGS into the PRF
increased REM sleep during the second hour (Figs 4 and
5). This increase in REM sleep time and in the number of
REM sleep episodes corresponds well with the time-course
of ACh release evoked by PRF dialysis administration of
CGS (Fig. 2). These results suggest that the increase in REM
sleep was caused, in part, by the significant increase in ACh
release elicited by CGS. This interpretation is consistent with
data showing that muscarinic receptors are present in mouse
PRF and contribute to REM sleep generation (DeMarco
et al. 2003; Coleman et al. 2004a; Douglas et al. 2005). In
the same area of the mouse PRF where administration of
CGS increased ACh release and increased REM sleep,
microinjection of the acetylcholinesterase inhibitor neostig-
mine produces a REM sleep-like state that is blocked by
muscarinic receptor antagonists (Lydic et al. 2002; Coleman
et al. 2004a; Douglas et al. 2005). CGS-evoked REM sleep
enhancement in rat is blocked by the muscarinic receptor
antagonist atropine (Marks et al. 2003). Considered together,
these data indicate that the increase in REM sleep caused by
CGS involves increased cholinergic neurotransmission at
muscarinic receptors in the PRF.
Dialysis administration of CGS (3 lM) also caused an
increase in NREM sleep (Fig. 4). This result was surprising,
because the PRF is not known to regulate NREM sleep, and
microinjection of CGS into rat PRF did not cause an increase
in NREM sleep (Marks et al. 2003). The differences in the
effect of CGS on NREM sleep between the previous (Marks
et al. 2003) and present (Fig. 4) studies may be because of
the route of drug administration (microinjection vs. micro-
dialysis), species (rat vs. mouse), and/or site of drug
administration within the PRF. Microinjection sites where
CGS was administered to rat were localized to caudal
portions of the PnO (Marks et al. 2003), whereas most of the
dialysis sites used for the present study were localized to
rostral portions of the PnC (Fig. 5c). A systematic mapping
study is required to determine if sites in the PnC are more
effective for producing NREM sleep following CGS admin-
istration than sites in the PnO.
Interestingly, NREM sleep was significantly increased
during the first hour of CGS delivery. In contrast, REM sleep
did not significantly increase until the second hour of CGS
delivery (Fig. 4). The neurochemical mechanisms underlying
these temporal differences in the response to CGS are not
addressed by the present data. Sleep is a genetically
modulated phenotype (Tafti and Franken 2002) and it is
not known to what extent the Fig. 4 data are true for other
strains of mice. The temporal differences in the NREM sleep
and REM sleep responses to CGS may, in part, reflect the
fact that B6 mice have seven times more NREM sleep than
REM sleep (Franken et al. 1999). The h 1 versus h 2 effects
of CGS on sleep may also vary as a function of species. B6
mice spend only 5 or 6% of total sleep time in the REM
phase of sleep (Franken et al. 1999). In contrast, cats spend
15 to 20% of total sleep time in REM sleep. Thus, the finding
that CGS caused an increase in NREM sleep before it
increased REM sleep may also reflect the comparatively
small amount of REM sleep characteristic of mice.
One mechanism by which adenosine A2A receptors in the
PRF may promote NREM sleep is by inhibiting the activity
of wakefulness generating neurons (Methippara et al. 2005).
Adenosine A2A receptors are located on GABAergic neurons
(Hettinger et al. 2001), and in vivo and in vitro data
demonstrate that adenosine A2A receptor stimulation increa-
ses GABA release (Mayfield et al. 1993; Ferre et al. 1994;
Mayfield et al. 1996). The dorsal raphe nucleus promotes
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wakefulness and receives GABAergic input from the PRF
(Luppi et al. 1999). In addition to adenosine causing sleep by
inhibiting neurons that promote arousal, there is support for
the view that adenosine may disinhibit neurons that actively
promote sleep (Morairty et al. 2004). These data support the
speculation that the excitatory actions of adenosine A2A
receptors in the PRF would enhance NREM sleep if
adenosine A2A receptors are localized to GABAergic neurons
that project to and inhibit serotonergic neurons in the dorsal
raphe nucleus. Adenosine has been shown to inhibit the
discharge of wakefulness-active neurons in the basal fore-
brain of rat (Alam et al. 1999) and cat (Thakkar et al. 2003).
NREM sleep is positively correlated with FOS activation in
the ventrolateral preoptic nucleus (Scammell et al. 2001).
For a subset of ventrolateral preoptic nucleus neurons there is
evidence that adenosine A2A receptors cause neuronal
activation (Gallopin et al. 2005).
Conclusion
The results indicate for the first time that acetylcholine
release in the pontine reticular formation and sleep are altered
by an adenosine A2A receptor agonist. This study provides
novel evidence that dialysis delivery of CGS to the PRF
significantly increases NREM sleep. Whether pontine CGS
increases NREM sleep by inhibiting wakefulness-promoting
systems can be addressed by future studies. The finding that
adenosine agonists and antagonists alter sleep and wakeful-
ness are consistent with the view that endogenous adenosine
contributes to arousal state control. This interpretation agrees
with the fact that the arousal-promoting effects of caffeine
result from blockade of A2A receptors (Huang et al. 2005).
The results presented here support the interpretation that
sleep is increased by endogenous adenosine, acting at A2A
receptors in the PRF.
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